ACE2 dysregulation has been revealed to be a major contributing factor to MetS progression, through mechanisms involving inflammation, stress states, structural remolding, and impairment of insulin signaling pathways (Cao et al., 2021). This evidence concerns the gene ACE2 and metabolic syndrome.